AMCZX
Price
$19.49
Change
+$0.04 (+0.21%)
Updated
Jul 31 closing price
Net Assets
294.35M
FSMAX
Price
$114.13
Change
-$0.47 (-0.41%)
Updated
Jul 31 closing price
Net Assets
40.08B
Interact to see
Advertisement

AMCZX vs FSMAX

AMCZX vs FSMAX Comparison Chart in %
View a ticker or compare two or three
VS
AMCZX vs. FSMAX commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMCZX is a Buy and FSMAX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
FSMAX has more cash in the bank: 40.1B vs. AMCZX (294M). FSMAX pays higher dividends than AMCZX: FSMAX (0.50) vs AMCZX (0.00). AMCZX was incepted earlier than FSMAX: AMCZX (11 years) vs FSMAX (15 years). AMCZX (0.92) is less costly to investors than FSMAX (0.04). AMCZX is a more actively managed with annual turnover of: 88.64 vs. FSMAX (23.00). FSMAX has a lower initial minimum investment than AMCZX: FSMAX (0) vs AMCZX (500000). FSMAX annual gain was more profitable for investors over the last year : 20.57 vs. AMCZX (8.16). FSMAX return over 5 years is better than : 33.18 vs. AMCZX (-14.65).
AMCZXFSMAXAMCZX / FSMAX
Total Expense Ratio0.790.042,257%
Annual Report Gross Expense Ratio0.920.042,629%
Fund Existence11 years15 years-
Gain YTD4.16913.37031%
Front LoadN/AN/A-
Min. Initial Investment5000000-
Min. Initial Investment IRAN/AN/A-
Net Assets294M40.1B1%
Annual Yield % from dividends0.000.50-
Returns for 1 year8.1620.5740%
Returns for 3 years49.4655.8389%
Returns for 5 years-14.6533.18-44%
Returns for 10 years90.04133.8267%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ESGV132.020.89
+0.68%
Vanguard ESG US Stock ETF
SPMV50.75N/A
N/A
Invesco S&P 500 Minimum Variance ETF
BNDP73.11-0.17
-0.23%
Vanguard Core-Plus Bond Index ETF
NIM9.16-0.03
-0.33%
Nuveen Select Maturities Municipal Fund
HQL19.10-0.34
-1.75%
abrdn Life Sciences Investors